Clinical Trial Update: Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating plamotamab plus tafasitamab and lenalidomide versus tafasitamab and lenalidomide in relapsed or refractory diffuse large B-cell lymphom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Plamotamab (plamotamab)
• tafasitamab (tafasitamab)

Snippet

Sponsor: Xencor, Inc. | Conditions: Diffuse Large-cell B-cell Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2024-04-30